Realbotix extends deadline for Onconetix deal to March 31, 2027
ONCO•Realbotix extended the deadline for its subsidiary RealLLC’s merger with Onconetix to March 31, 2027, from November 30, 2026. The amended agreement removes Onconetix’s minimum net cash closing condition; Realbotix would retain a 75%-95% stake, and Onconetix has advanced RealLLC $3 million.
1. Amended merger terms
Realbotix extended the deadline for its subsidiary RealLLC’s merger with Onconetix to March 31, 2027, from November 30, 2026. The transaction would list RealLLC’s robotics and AI business on Nasdaq, with closing expected before the end of the first quarter of 2027. Realbotix would retain a 75%-95% ownership stake and appoint four of Onconetix’s five directors at closing. The amended agreement removes Onconetix’s minimum net cash closing condition, and Onconetix has advanced RealLLC $3 million toward completing the transaction.
